Business trends
Drugmakers tap cutting-edge tech to fight pollen allergies
Japan's Torii offers immunotherapy while Novartis turns to antibodies
Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Pharmaceuticals
Opinion
Itochu versus Descente -- investors stuck in the middle
Trader's bid to up stake in sportswear maker Descente highlights Japan's systemic conflicts of interest
Opinion
Japan's lopsided M&A boom
Nation's companies invest record amounts abroad, but foreign groups steer clear of Japan
Companies
Dr. Reddy's restarts Suboxone sales in US after court clearance
Indivior's U.S. unit also launches generic version of the drug
Opinion
Indian R&D -- time to solve the puzzle
Why does a country with so much research talent produce little homegrown innovation?
Companies
Sun Pharmaceutical quarterly profit jumps fourfold amid gains in US business
Company prepares to launch new drug in US coming months
Companies
Dr. Reddy's Laboratories posts better-than-expected profit on sale of unit
Lower taxes during third-quarter also boosted net income
Companies
Sun Pharmaceutical restructures India business after second whistleblower complaint
Distribution related to domestic drug formulations will be shifted to own unit
Business deals
Takeda and rivals chase cancer therapy prize through M&A
Shire's profits needed to fund drugmaker's hunt for next-gen treatments
Business deals
Japan's MUFG extends $18bn loan to Bristol-Myers for megadeal
Megabank teams with partner Morgan Stanley to fund Celgene acquisition
